FDA approves Wegovy-like GLP-1 pill, Foundayo, for weight loss

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity , or overweight with weight-related medical problems. This approval makes Eli Lilly’s oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug available in pill form, after Wegovy , which gained approval in December 2025.

In March 2026, a phase 3 clinical trial for oral orforglipron suggests it can lower blood sugar levels at least as well as, and in some cases better than, oral semaglutide. Foundayo is notable not only for its oral formulation but also for being among the first medications approved under the FDA’s new Commissioner’s National Priority Voucher (CNPV) program , an initiative designed to accelerate access to treatments that address major public health needs.

GLP-1 receptor agonists have transformed the management of obesity and type 2 diabetes in recent years. Evidence suggests roughly one in eight U.S.

adults report having ever used GLP-1 medication, with 6% currently using such drugs.